| 靶点: |
ADAM-17;IC50: 31.6 μM (Tyrosine phosphatase);Ki: 26.22 μM (Tyrosine phosphatase) |
| 体内研究: |
ZLDI-8 (0.2-2 mg/kg; intraperitoneal injection; every two days; for 20 days; nude mice) treatment enhances the effect of Sorafenib on inhibiting tumor growth in nude HCC-bearing mice model. |
| 参考文献: |
1. Zhang Y, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018 Jul 3;9(7):743. 2. Hou X, et al. Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening. J Med Chem. 2014 Nov 26;57(22):9309-22. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.307 ml |
11.534 ml |
23.068 ml |
| 5 mM |
0.461 ml |
2.307 ml |
4.614 ml |
| 10 mM |
0.231 ml |
1.153 ml |
2.307 ml |
| 50 mM |
0.046 ml |
0.231 ml |
0.461 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |